- Home
- / TOLREMO therapeutics
TOLREMO therapeutics
Total Funding
$11.9 M
TOLREMO therapeutics Summary
Company Summary
- Overview
- TOLREMO therapeutics is a company that aims to prevent resistance development in cancer. It develops small molecules to target drug resistance pathways in cancer therapy. Its solution eradicates cancer cells that cause drug resistance.
- Type
- Private
- Status
- Active
- Founded
- 2017
- HQ
- Muttenz, CH | view all locations
- Website
- https://www.tolremo.com/
- Cybersecurity rating
Table of Contents
Key People
Guido Hartmann, COO/Head Translational Sciences
Reinhard Ambros, Chairman of the Board
Isaac Kobrin, Director
LocationsView all
1 location detected
Muttenz, BL HQ
Switzerland
Hofackerstrasse 40